The Novartis diabetes drug Starlix failed to reduce progression to the disease or cut down on serious heart problems in patients at high risk for both diabetes and heart disease, according to a large study released on Sunday. The 9,306-patient study tested Starlix, known chemically as nateglinide, and the big-selling Novartis blood pressure medicine Diovan.
Diovan, known chemically as valsartan, reduced progression to diabetes by 14 percent compared to a placebo but failed to reduce the risk of serious heart problems, such as heart attack and stroke, according to researchers who presented the data at the American College of Cardiology scientific meeting in Atlanta.
The failure of Starlix to provide benefit to these patients and lack of heart impact by Diovan came as a surprise to researchers.
Novartis drugs fail to help high-risk patients
